Osteoporosis Medication and Dental Implants: What 2025 Research Says

Short answer: A major 2025 international review and consensus statement concluded that most people taking osteoporosis medications (bisphosphonates or denosumab) do not need to stop them before getting a dental implant. Reviews have been mixed and mostly low-certainty. The 2025 consensus did not find a clear association with implant failure, but some pooled analyses show a possible increase that was not always statistically significant. Jaw osteonecrosis does occur, but the absolute rate is low with osteoporosis-level dosing. The evidence is still maturing, so a careful, individual plan with your dentist and physician matters.

What did the 2025 research conclude?

In 2025, an international taskforce published a systematic review and consensus statement on osteoporosis drugs and dental implants. It reached three main conclusions:

• Patients with osteoporosis generally do not need to pause their antiresorptive medication before implant placement.
• The consensus did not find a clear association between these medications and implant failure, although some pooled analyses show a possible increase.
• Long-term bisphosphonate use may add a small absolute amount of risk for osteonecrosis of the jaw, roughly 3 cases per 1,000 patients. The authors described the certainty of that estimate as moderate. The relative risk is higher than in people who do not take the drug, even though the absolute risk is low. This figure applies to bisphosphonates; data on denosumab are more limited.

The panel labeled its recommendation about continuing medication as a weak one resting on very low-quality evidence. In other words, it is a considered position, not a final word.

A separate 2025 meta-analysis of observational studies did not find a statistically significant increase in implant failure with bisphosphonates. Earlier pooled analyses were mixed, and some reported a higher failure risk, so overall certainty remains low.

Why do osteoporosis and cancer treatment carry different risks?

Osteonecrosis of the jaw (sometimes called ONJ or MRONJ) is a condition where an area of jawbone is slow to heal and may become exposed. It is the main concern people raise about these medications, and it helps to know that the dosing is very different depending on why someone takes the drug.

• Osteoporosis therapy uses lower doses, typically given as a pill or as an occasional infusion or injection, to strengthen bone and prevent fractures.
• Cancer-related therapy uses much higher doses on a more frequent schedule to protect bone from tumor effects.

Reported osteonecrosis rates are much higher in the high-dose cancer setting. Dental professionals have long advised that osteoporosis patients should not abandon their medication out of fear, because stopping it can raise the risk of fractures, including spinal fractures. Studies of implants in people on high-dose therapy are very limited. Those patients need a more individualized discussion that involves their oncology team.

What does the evidence not show yet?

It's worth being clear about the limits of the current research:

• Much of the data is observational. Randomized trials in this area are lacking, and many studies are retrospective or small.
• Denosumab data is thinner. Direct implant studies of denosumab are fewer, so conclusions about it lean more on the broader consensus than on direct implant studies.
• Long-term follow-up is still developing. Follow-up in many studies is short, so long-term outcomes are less certain. This is why regular check-ups remain important.
• Individual factors matter. Gum health, smoking, diabetes, how long you've taken the medication, and the dose all play a role, and many studies did not capture them well.

One recent review also suggested that implants themselves may not raise osteonecrosis risk in people on low-dose medications. It found that tooth extractions were linked to higher risk than implant placement. The authors cautioned that the follow-up in those studies was short.

How do dentists typically plan implants for patients on these medications?

Dentists often take a coordinated approach. Here is what that usually looks like:

1. A full medication history. Which drug you take, the dose, how you take it, and for how long.
2. Coordination with your physician. Your prescribing doctor knows why you need the medication. A dentist will typically involve them before any change is considered, and you should never stop an osteoporosis drug on your own.
3. Imaging and a gum and bone evaluation. Healthy gums and good bone support improve results for any implant patient.
4. Careful, gentle surgical technique. Minimizing trauma to the bone and soft tissue supports healing.
5. A dependable maintenance plan. Regular cleanings and implant check-ups help catch small problems early.

Any decision about timing a procedure around doses, or pausing a medication (sometimes called a drug holiday), belongs to your prescribing physician and dentist together and is not routinely recommended. If an urgent dental problem comes up, emergency care should not be delayed.

Common questions about osteoporosis medication and dental implants

Q: Should I stop my osteoporosis medication before getting an implant?

Current consensus says that usually isn't necessary. Please don't pause or stop any prescribed medication without talking to your physician first, since stopping can raise fracture risk. Whether to continue, adjust, or time your medication is a decision for you and your prescribing physician.

Q: Does a bisphosphonate or denosumab make implants more likely to fail?

The evidence is mixed and mostly low-certainty. The 2025 consensus did not find a clear association with implant failure, and a 2025 meta-analysis of observational studies did not find a statistically significant increase with bisphosphonates. However, some pooled analyses show a possible increase that was not always statistically significant. The evidence is still maturing, particularly for denosumab and for long-term outcomes.

Q: How common is jaw osteonecrosis for people taking osteoporosis medication?

It is uncommon. Long-term bisphosphonate use may add roughly 3 cases per 1,000 patients. The relative risk is higher than in people not taking the drug, even though the absolute risk is low. Denosumab data are more limited, and the risk is much higher with the high-dose regimens used in cancer care.

Q: What can I do to lower my risk?

Keep your gums healthy, attend regular dental visits, tell every provider which bone medications you take, and report any lingering soreness, loose teeth, or slow-healing areas in your mouth promptly.

Planning an implant while on osteoporosis medication

If you live in Belmont or elsewhere in San Mateo County and are weighing an implant while taking osteoporosis medication, a consultation is a good first step. Bring a list of your medications and your prescribing physician's contact information. Costs vary with the complexity of each case, and our team can give you a written estimate after your visit. We accept many PPO plans (call to verify your coverage), offer in-house membership plans, and have 0% APR financing options through CareCredit and Proceed Finance with approved credit; terms and eligibility vary. To schedule a consultation, call (650) 591-1984 or visit carlmontdentalcare.com.

This article is for general education and is not a substitute for personal medical or dental advice. Always consult your physician and dentist about your own situation.